Disease outbreak news 30 October 2018
Vaksen MMRV (Lawoujòl, Malmouton,
Ribeyòl, ak Varisèl): Sa Ou Dwe Konnen
Evolving Patterns of Worldwide Distribution as of 14thFebruary 2021
Extract from report of GACVS meeting of 3-4 December 2009, published in the WHO Weekly Epidemiological Record on 29 January 2010
Many critical questions remain about the effectiveness of COVID-19 vaccines in real-world settings. These questions can only be answered in post-introduction vaccine effectiveness studies.This guidance document outlines an approach to leverage existing surveillance systems for Severe Acute Respirato...ry Infection (SARI) to estimate COVID-19 vaccine effectiveness (VE) in preventing SARI associated with laboratory-confirmed SARS-CoV-2 using existing SARI surveillance systems. The approach uses the test-negative design to evaluate VE; cases are SARI patients who tested positive for SARS-CoV-2, and controls are SARI patients who tested negative for SARS-CoV-2.
more
an operational guide to support all those responsible for planning and implementing the rollout of COVID-19 vaccine to refugees and migrants at national and local levels, 14 March 2022
Health workers involved in deployment and implementation of COVID-19 vaccination require vaccine-specific knowledge to ensure safe and efficient vaccine delivery. This training provides key information about COVID-19 vaccines through short instructional videos, vaccine explainers, job aids, topic br...iefings, and downloadable presentations. It builds on the COVID-19 vaccination training for health workers and the Orientation to National Deployment and Vaccination Planning for COVID-19.
Please note that further videos and resources concerning other vaccines will be added as they receive emergency use listing (EUL) or prequalification. Available in different languages
more
This drill package is part of a broader COVID-19 simulation exercise package, including vaccine tabletop exercises(TTX). For exercises to be most effective, it is recommended they should be part of a comprehensive programme made up of progressively complex exercises, each exercise ... building on the previous one until they are as close to reality as possible
Available in English, Arabic, Chinese, French, Russian, Spanish and Portuguese
more
Adaptable guidance, tools, trainings, and advocacy materials are being developed to support countries in preparing for COVID-19 vaccination. Please visit this page regularly for updates.
Comment The Lancet Volume 397, ISSUE 10269, P72-74, January 09, 2021
Published:December 08, 2020DOI:https://doi.org/10.1016/S0140-6736(20)32623-4
13 July 2021
The module provides an overview of factors to consider when monitoring the safety of COVID-19 vaccines administered to pregnant and breastfeeding women. It describes how national routine AEFI surveillance should be adapted to cater for this specific group of population using both pass...ive and active surveillance methods. Specific considerations and limitations of each method are provided as well as tools for implementation.
more
This is an e-learning module with the objective of providing education for health professionals and pregnant women using published results and studies based on COVID-19 surveillance data, which have indicated an increased risk among pregnant women of presenting with severe forms of COVID-19 and, the...refore, of being hospitalized and admitted to intensive care units.
more
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
An overview of COVID-19 Vaccine AstraZeneca and why it is authorised in the EU. Available in 22 languages
18 Febr. 2021
Version 2.3 , 21 April 2022. The CVIC tool supports credible COVID-19 vaccination costing to facilitate a dialogue with stakeholders, while maintaining sensitivity to protect essential health services.
The CVIC tool provides a structured and comprehensive estimation of incremental operational and... selected capital costs of introducing and deploying COVID-19 vaccines, in alignment with the National Deployment and Vaccination Plan (NDVP). This is essential for resource mobilization, budgeting, and delivery strategy refinement and optimization. The tool has been pre-populated with data from global databases and provides a total cost estimate over an immunization programme over the period of 2021-2023, after which COVID-19 vaccination is expected to be integrated into national immunization plans. Countries can customize the priority target populations based on WHO SAGE guidance and select multiple delivery strategies and vaccine products. The tool is available in all six UN working languages (Arabic, Chinese, English, French, Russian and Spanish) and Portuguese. An e-learning course on CVIC is available at OpenWHO.
In this updated version 2.3 of the tool, some minor bugs have been fixed and new features have been added
more